Cardiostim 2016: Growing Importance of Remote Monitoring and Potential for New Heart Monitor Indications Detailed at Scientific Session

Experts Stress Need for Robust Remote Monitoring, Highlight how New Indications for Insertable Cardiac Monitors Could Expand Patient Care

NICE, France and BERLIN, Germany, June 9, 2016 -- BIOTRONIK Home Monitoring® received strong endorsements during the Cardiostim scientific session “Improving Patient Outcomes in Arrhythmia Management.”

Every year, more than a million new patients worldwide receive a pacemaker, ICD, or CRT-D implant, pointing to the need for efficient monitoring and follow-up. Experts highlighted that Home Monitoring reduces mortality1 and hospitalization,2 while also reducing health care costs.3, 4

“Efficient workflow and robust transmissions are critical to leveraging the benefits of remote monitoring,” said Dr. Niraj Varma, Cleveland Clinic, US. “BIOTRONIK Home Monitoring facilitates this with daily automatic transmissions that preserve the highest order of data integrity, and are yet easy to handle. This is a key reason why this system has been associated with improved clinical outcomes in several trials and why current remote monitoring guidelines are based largely on Home Monitoring data.”

Speakers also discussed the rising importance of using remote monitoring with insertable cardiac monitors (ICMs) to enable earlier diagnosis and prevention in patients who have arrhythmias, but are not yet indicated for a pacemaker or ICD. As one example, there are currently an estimated 10 million atrial fibrillation patients in Europe alone.5

“We have strong data on the clinical benefits of remote monitoring and ICMs,” said Dr. Jan Steffel, University Hospital Zurich, Switzerland. “There are certainly reasons to explore future indications in addition to atrial fibrillation, something the BIOGUARD-MI study6 is currently looking at. These could include ventricular tachycardia, atrial fibrillation after myocardial infarction, and heart failure. I expect the need for ICMs and remote monitoring will continue to rise.”

Finally, attendees got a closer look at the first-in-human study of BioMonitor 2, BIOTRONIK’s new ICM. The pilot study showed that the heart monitor can be inserted in as little as two minutes. It also observed high R-wave amplitudes and a greater than 90 percent success rate for daily Home Monitoring transmissions.

“For ICMs to have a significant impact on early arrhythmia diagnosis, reliable detection including sensing, data quality and transmission is critical,” commented Dr. Sze-Yuan Ooi, Prince of Wales Hospital, Sydney, Australia. “This study shows promising results for BioMonitor 2 in all of these fields. The high transmission success rate is key because we need robust, high-integrity data for our patients to derive the maximum benefit.”

  1. Hindricks G et al. The Lancet. 2014, 384(9943).
  2. Varma V et al. Circulation. 2010, 122(4).
  3. Guedon-Moreau L et al. Europace. 2014, 16(8).
  4. Heidbuchel H et al. Presentation at ESC Congress 2014.
  5. Zoni-Berisso M et al. Clin Epidemiol. 2014, 6.
  6. BIOTRONIK Home Monitoring in patients with preserved left ventricular function after diagnosed acute myocardial infarction.


At BIOTRONIK, patient well-being is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular and endovascular solutions. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.